You are here

Michael Datto

Associate Professor, Director DUHS Clinical Molecular Diagnostics Laboratory
(919) 684-2698
Research Interest: 
Signal transduction
Research Summary: 
Development of multigene assays to determine cancer patient-specific prognoses.
Research Description: 

Dr. Datto is a AP/CP/MGP board certified pathologist who specializes in molecular pathology. He is director of the Duke University Health System Clinical Molecular Diagnostics Laboratory. This CAP/CLIA certified laboratory does the majority of the DNA and RNA based high complexity molecular diagnostic testing for Duke patients and health care providers. Testing includes full gene sequencing and targeted mutation analysis for inherited diseases, targeted mutation and polymorphism analysis for somatic mutations in a variety of tumor types and disease conditions for prognostics and pharmacogenomic applications and quantitative analysis for viral load and minimal residual disease testing in patients with leukemias and lymphomas.

Dr. Datto also has an independent research program developing multigene assays to determine cancer patient specific prognoses in the context of breast and colon cancer with the ultimate goal of producing improved molecular diagnostic assays. The ultimate goal of this truly translational effort is the incorporation of genome wide expression profiling for prognosis and diagnosis into the clinical laboratories for routine patient care. This involves the study of factors that affect the precission and accuracy array-based predictors, as well as deriving novel diagnostic molecular targets. Finally, Dr. Datto has a strong research interest in resident and medical student education, specifically the development of web-base community tools for anatomic and clinical pathology education.

Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.
Kernagis DN, Hall AH, Datto MB.
J Mol Diagn. 2012. 14:214-22.

Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.
Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB.
J Clin Oncol. 2010. 28:2198-206.

NDRG4 is required for cell cycle progression and survival in glioblastoma cells.
Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich JN, Wang XF, Datto MB.
J Biol Chem. 2009. 284:25160-9.